Endothelial cells as therapeutic targets in cancer: New biology and novel delivery systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 20, Issue 2-3, 2003, Pages 139-152

  Murray, J C ^a   Moghimi, S M ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

Antitumor therapy; Drug delivery systems; Human vascular map; Integrins; Peptidomimetics; Phage display technology; Tumor neovasculature

Indexed keywords

ALPHAVBETA3 NP PEPTIDE; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; BIAPCITIDE; BLEOMYCIN; COMBRETASTATIN A4; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FUMAGILLOL; FUMAGILLOL CHLOROACETYLCARBAMATE; MELPHALAN; MEMBRANE PROTEIN; NONAPEPTIDE; PEPTIDE; PEPTIDE LIBRARY; PEPTIDOMIMETIC AGENT; POLYETHYLENEIMINE; SYNTHETIC PEPTIDE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINCA ALKALOID;

CANCER; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; LIVER TOXICITY; LYMPH VESSEL ENDOTHELIUM; NONHUMAN; PHAGE DISPLAY; REVIEW; TUMOR VASCULARIZATION;

DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0141894030     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23.20     Document Type: Review

References (68)

1. McCarty MF, Liu W, Fan F, Parikh A, Reimuth N, Stoeltzing O, Ellis LM. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trend Mol Med 2003; 9: 53-58.
2. Molema G, Griffioen AW. Rocking the foundation of solid tumor growth by attacking the tumor's blood supply. Immunol Today 1998; 18:392-394.
3. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular disease, and chronic inflammation. Pharmacol Rev 2000; 52:237-268.
4. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/Flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56:1324-1330.
5. Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 1997; 73:865-870.
6. Sato TN, Tozawa Y, Deutsch U, Wolburg Buchholz K, Fujiwara Y, Gendron Mguire M, Gridely T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376:70-74.
7. Davol P, Beitz JG, Mohler M, Ying W, Cook J, Lappi DA, Frackelton AR Jr. Saporin toxins directed to basic fibroblast growth-factor receptors effectively target human ovarian teratocarcinoma in an animal model. Cancer 1995; 76:79-85.
8. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997; 3:1031-1044.
9. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999; 5:371-382.
10. Griffioen AW, Coenen MJH, Damen CA, Hellwig SMM, Van Weering DHJ, Vooys W, Blijham GH, Groenewegen G. CD44 is an activation antigen on human endothelial cells, involvement in tumor angiogenesis. Blood 1997; 90:1150-1159.
11. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nature Biotechnol 1997; 15:1271-1275.
12. Molema G, Kroesen BJ, Helfrich W, Meijer DKF, de Leij LFMH. the use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy. J Control Release 2000; 64:229-239.
13. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu ZP, Hackett NR, Crystal RG, Moore MAS, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and haematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med 2001; 7:1194-1201.
14. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Rev Cancer 2002; 2: 826-835.
15. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Bannerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis. EMBO J 2001; 20:672-682.
16. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Med 2001; 7:186-191.
17. Fukuda H, Yamada T, Kamata S, and Saitch H. Anatomic distribution of intraprostatic lymphatics: implications for the lymphatic spread of prostate cancer-a preliminary study. Prostate 2000; 44:322-327.
18. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med 2001; 7:192-198.
19. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001; 7:462-468.
20. Leu AJ, Berk DA, Lymboussaki, Alitalo K, and Jain RK. Absence of functional lymphatics within murine sarcoma: a molecular and functional evaluation. Cancer Res 2000; 60:4324-4327.
21. Jackson DG, Prevo R, Clasper S, and Banerji S. LYVE1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2000; 22:317-321.
22. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999; 154:385-394.
23. Carreira CM, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI, Jain RK. LYVE1 is not restricted to the lymph vessels: expression in normal liverblood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001; 61:8079-8084.
24. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science 2000; 289:1197-1202.
25. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-1317.
26. Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as a target for therapy. Curr Opin Chem Biol 2001; 5:308-313.
27. Rajotte D, and Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J Biol Chem 1999; 274:11593-11598.
28. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60:722-727.
29. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. Nature Med 2002; 8:121-127.
30. Schirner M. Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev 2000; 19:67-73.
31. Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998; 4:1331-1336.
32. Ingber D, Fujita T, Kishimoto S, Sudo S, Kanamura T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990; 348:555-557.
33. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A-4 phosphate. Anticancer Res 1999; 19:189-195.
34. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29:10-14.
35. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328.
36. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
37. Lee TH, Rhim T, Kim SS. Prothrombin kringle-2 domain has a growth inhibitory acitivity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 1998; 273:28805-28812.
38. Parr C, Hiscox S, Nakamura T, Matsumoto K, Jiang WG. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int J Cancer 2000; 85:563-570.
39. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramachandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275:1209-1215.
40. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 286:1028-1032.
41. Eliceiri BP, Cheresh DA. The role of alpha v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103:1227-1230.
42. Kim S, Bell K, Mousa SA, Varner JA. A regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol 2000; 156:1345-1362.
43. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KCP. Detection of tumor angiogenesis in vivo by alpha(v)beta(3)-targeted magnetic resonance imaging. Nat Med 1998; 4:623-626.
44. Assa-Munt N, Jia X, Laakkonen P, and Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001; 40: 2373-2378.
45. Arap W, Pasqualini R, and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-380.
46. Zitzmann S, Ehemann V, and Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 2002; 62:5139-5143.
47. Schraaa AJ, Kok RJ, Berendsen AD, Moorlag HE, Bos EJ, Meijer DKF, de Leij LFMH, Molema G. Endothelial cells internalise and degrade RGD-modified proteins developed for tumor vasculature targeting. J Control Releaseease 2002; 83:241-251.
48. Wickham TJ. Targeting adenovirus. Gene Ther 2000; 7:110-114.
49. Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang MH, Naito S, Lei XS, Hemminki A, Carey D, Curiel DT. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 2002; 62:4273-4281.
50. Turunen MP, Puhakka HL, Koponen JK, Hiltunen MO, Rutanen J, Leppanen O, Turunen AM, Narvanen A, Newby AC, Baker AH, Yla-Herttuala S. Peptide retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther 2002; 6:306-312.
51. Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000; 102:231-237.
52. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2000; 62:867-874.
53. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2000; 110:475-482.
54. Laakkonen P, Porkka K, Hoffman AJA, Ruoslahti E. Tumor-homing peptide with a targeting specificity related to lymphatic vessel. Nat Med 2002; 8:751-755.
55. Hallahan D, Geng L, Qu SM, Scarfone C, Giorgio T, Donnelly E, Gao X, Clanton J. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 2003; 3:63-74.
56. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404-2407.
57. Kiani MF, Yuan H, Chen X, Smith L, Gaber MW, Goetz DJ. Targeting microparticles to select tissue via radiation-induced upregulation of endothelial cell adhesion molecules. Pharm Res 2002; 19:1317-1322.
58. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91:3527-3561.
59. McLean JW, Fox EA, Baluk P, Bolton PB, Haskell A, Pearlman R, Thurston G, Umemoto EY, McDonald DM. Organ-specific endothelial uptake of cationic liposome-DNA complexes in mice. Am J Physiol 1997; 273:H387-H404.
60. Moghimi SM, Patel HM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system. The concept of tissue specificity. Adv Drug Deliv Rev 1998; 32:45-60.
61. Moghimi SM, Hunter AC. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm Res 2001; 18:1-8.
62. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101:1401-1413.
63. Suh W, Han SO, Yu L, Kim SW. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol Ther 2002; 6:664-672.
64. Moghimi SM, Hunter CH, Murray JC. Long-circulating and target-specific nanoparticles; theory to practice. Pharmacol Rev 2001; 53:283
65. Reynolds AR, Moghimi SM, Hodivala-Dilke K. Nanoparticle-mediated gene delivery to tumor neovasculature. Trend Mol Med 2003; 9:2-4.
66. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003. [In press.]
67. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58:4646-4653.
68. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manora K, Bebezra R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumor xenografts. Nature 1999; 401:670-677.